Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

NCT06871007 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.

NCT NCT06871007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06871007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Lead sponsor
St. Petersburg State Pavlov Medical University
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
September 1, 2024
Completion date
September 1, 2031
Enrollment
22 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

children, nivolumab, primary mediastinal (thymic) large b-cell lymphoma